Table 2.
| DEP blood |
Qiagen plasma |
Genomic DNA |
||||
|---|---|---|---|---|---|---|
| ID | V-gene/allele | V-region ID, % | V-gene/allele | V-region ID, % | V-gene/allele | V-region ID, % |
| CLL-1 | IGHV4-39*01 F | 95.5 | IGHV4-39*01 F | 95.5 | IGHV4-39*01 F | 95.5 |
| CLL-2 | IGHV1-69*01 F | 100.0 | IGHV1-69*01 F | 100.0 | IGHV1-69*01 F | 100.0 |
| CLL-3 | IGHV3-30*03 F | 95.1 | IGHV3-30*03 F | 95.1 | IGHV3-30*03 F | 95.1 |
| CLL-4 | IGHV1-2*02 F | 100.0 | IGHV1-2*02 F | 100.0 | IGHV1-2*02 F | 100.0 |
| CLL-5 | IGHV4-4*07 F | 100.0 | IGHV4-4*07 F | 100.0 | IGHV4-4*07 F | 100.0 |
| CLL-6 | IGHV1-8*01 F | 100.0 | IGHV1-8*01 F | 100.0 | IGHV1-8*01 F | 100.0 |
| CLL-7 | IGHV3-21*02 F | 88.2 | IGHV3-21*02 F | 88.2 | IGHV3-21*02 F | 88.2 |
| CLL-8 | IGHV3-33*01 F | 94.1 | IGHV3-33*01 F | 94.1 | IGHV3-33*01 F | 94.1 |
| CLL-9 | IGHV1-69*01 F | 100.0 | IGHV1-69*01 F | 100.0 | IGHV1-69*01 F | 100.0 |
| CLL-10 | IGHV3-53*04 F | 97.2 | IGHV3-53*04 F | 97.2 | IGHV3-53*04 F | 97.2 |
| CLL-11 | IGHV3-64*01 F | 94.8 | IGHV3-64*01 F | 94.8 | IGHV3-64*01 F | 94.8 |
| CLL-12 | IGHV3-48*03 F | 99.0 | IGHV3-48*03 F | 99.0 | IGHV3-48*03 F | 99.0 |
| CLL-13 | IGHV4-39*01 F | 96.9 | IGHV4-39*01 F | 96.9 | IGHV4-39*01 F | 96.9 |
| CLL-14 | IGHV4-34*01 F | 99.3 | IGHV4-34*01 F | 99.3 | IGHV4-34*01 F | 99.3 |
| CLL-15 | IGHV4-39*01 F | 100.0 | IGHV4-39*01 F | 100.0 | IGHV4-39*01 F | 100.0 |
a
DNA sequencing results for ccf-DNA isolated from CLL blood samples by DEP and ccf-DNA isolated from CLL patient plasma samples by Qiagen process compared with the results obtained using an established method performed on genomic DNA obtained from CLL patient leukemic cells.
b
IGHV4-39, IGHV1-69, IGHV3-30, IGHV1-2, IGHV4-4, IGHV1-8, IGHV3-21, IGHV3-33, IGHV1-69, IGHV3-53, IGHV3-64, IGHV3-48, IGHV4-34, immunoglobulin heavy variables 4–39, 1–69, 3–30, 1–2, 4–4, 1–8, 3–21, 3–33, 1–69, 3–53, 3–64, 3–48, and 4–34, respectively.